<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) July 27, 2000
----------------
BOSTON LIFE SCIENCES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-6533 87-0277826
-------- ------ ----------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification No.)
incorporation or organization) File No.)
137 Newbury Street
8th Floor
Boston, Massachusetts 02116
--------------------------------------- ------------------
(Address of principal executive offices) Zip Code
</TABLE>
Registrant's telephone number, including area code (617) 425-0200
-----------------
<PAGE>
Item 5. Other Events.
-------------
On July 27, 2000 the Company announced that the results of its Phase III
clinical trial of Altropane as a diagnostic for Parkinson's Disease ("PD") had
successfully confirmed Altropane's ability to differentiate Parkinson's movement
disorders (including Parkinson's Disease) from other movement disorders. The
primary efficacy endpoints, "Specificity" and "Sensitivity" were both
statistically significant. The Company's Phase II clinical trial previously
demonstrated Altropane's utility in differentiating normal patients from those
with PD.
The multi-center Phase III study was designed to assess the Sensitivity and
Specificity of Altropane-SPECT scanning in a sample population representative of
those individuals that consult with neurologists or internists for undiagnosed
movement disorders. The study enrolled 95 subjects having the clinical
diagnosis of Parkinsonian Syndrome ("PS") and 70 patients having non-
Parkinsonian Syndrome movement disorders with clinical features similar to PS.
These clinical diagnoses were made by expert neurologists specializing in
movement disorders. Altropane-SPECT scans were performed on each subject and
were reviewed by an independent three-member panel of nuclear medicine
physicians specializing in neuroimaging, none of whom had knowledge of the
clinical diagnosis. The Altropane scans were read and categorized as being
consistent with either PS or non-PS, and were then compared to the expert
clinical diagnosis. Specificity was 86%, Sensitivity was 75%, and overall
accuracy was 80%. Only six scans (out of 160) could not be read due to
technical or other difficulties, and there were no Altropane-related adverse
events reported in the study.
Item 7. Exhibits.
---------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated July 27, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: August 1, 2000 By: /s/Joseph Hernon
-------------------------
Joseph Hernon
Chief Financial Officer
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit No. Page
----------- ----
<S> <C> <C>
99.1 Press Release, dated July 27, 2000 4
</TABLE>
